OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
BURLINGTON, Mass., Aug. 30, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 2017 Wells Fargo Healthcare Conference on Wednesday, September 6, 2017 at 9:40am ET at the Westin Waterfront Hotel in Boston, Mass.
To access the live webcast and subsequent archived recording of the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion Therapeutics (Nasdaq:FLXN) is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis. The company’s core values are focus, ingenuity, tenacity, transparency and fun. Flexion was named one of the Boston Business Journal's 2017 Best Places to Work.
Contact: Scott Young Sr. Director, Corporate Communications & Investor Relations Flexion Therapeutics, Inc. T: 781-305-7194 [email protected]
